A PRO assessment was performed on the four identified risks. For each of the risks the estimated cost of mitigating the risk (investment) was determined; the enterprise net present value (NPV) protected was calculated given the investment was made; and, the investment productivity (a.k.a return on investment) for each investment was calculated. The following table summarizes this information.

Risk	Investment $ (Millions)	NPV $ (Millions)	Investment Productivity
Unreported Adverse Effects	2	120	55.70
FDA Hold for Adverse Effects	15	335	18.65
Delay in Clinical Trial Enrollment	4	550	128.50
Rewrite FDA Submission	3	88	25.10

1. If the top three most productive investments were approved for implementation, what would be the total investment and how much enterprise value would be protected as measured in NPV?